Clinical Trial

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Name: A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma — clinical trial record (NCT07312188)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma.

Trial Details

NCT Number	NCT07312188
Lead Sponsor	Shandong New Time Pharmaceutical Co., LTD
Conditions	Relapsed or Refractory Multiple Myeloma
Enrollment	90 participants
Start Date	2025-07-02
Primary Completion	2028-05-20 (estimated)
Study Completion	2028-05-20 (estimated)
Updated on ClinicalTrials.gov	2025-12-31